Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus RECLAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus RECLAST.
ACTONEL vs RECLAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl diphosphate synthase (FPPS), a key enzyme in the mevalonate pathway, leading to disruption of osteoclast activity and induction of apoptosis.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
5 mg intravenously over at least 15 minutes once yearly for osteoporosis.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
The terminal elimination half-life of zoledronic acid in plasma is approximately 146 hours (range 76-250 hours) due to slow release from bone. Clinically, this supports a once-yearly dosing interval for osteoporosis.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Primarily renal; unchanged drug is excreted in urine. Approximately 50% of an absorbed dose is excreted unchanged in urine within 24 hours. The remainder is eliminated via renal excretion over an extended period, with negligible fecal or biliary elimination.
Category C
Category C
Bisphosphonate
Bisphosphonate